Next-Gen Paradigm Insulin Pump Will Incorporate MiniMed Glucose Sensor
This article was originally published in The Gray Sheet
Executive Summary
Medtronic MiniMed plans to begin a prospective, randomized, multi-center clinical trial this fall to support a PMA filing for the Paradigm 522/722 sensor-augmented insulin pump system
You may also be interested in...
Pipeline Technologies In Brief
Medtronic diabetes care update: Firm will initiate full market release of its Guardian continuous glucose monitoring system, PMA-approved in January, into the $3 bil. blood glucose monitoring market by February 2005, CFO Bob Ryan notes Dec. 1 at the Lazard Life Sciences Conference in New York. In FY 2006, Medtronic plans to launch the next-generation Guardian RT, capable of displaying a patient's "real time" glucose value in five-minute intervals, he added. The company expects to integrate Guardian RT with its Paradigm sensor-augmented insulin pump technology, as part of the effort to develop a closed-loop, external artificial pancreas for diabetic patients by 2008 (1"The Gray Sheet" June 21, 2004, p. 26). Ryan also reported Medtronic is conducting a clinical trial to drive insulin pump therapy penetration. The study will compare insulin pumps with multiple daily injections. The exec believes that a device capable of dropping the HbA1c levels in Type 1 diabetic patients to 7% could lower diabetes healthcare costs by $100 bil. over the next 10 years...
Pipeline Technologies In Brief
Medtronic diabetes care update: Firm will initiate full market release of its Guardian continuous glucose monitoring system, PMA-approved in January, into the $3 bil. blood glucose monitoring market by February 2005, CFO Bob Ryan notes Dec. 1 at the Lazard Life Sciences Conference in New York. In FY 2006, Medtronic plans to launch the next-generation Guardian RT, capable of displaying a patient's "real time" glucose value in five-minute intervals, he added. The company expects to integrate Guardian RT with its Paradigm sensor-augmented insulin pump technology, as part of the effort to develop a closed-loop, external artificial pancreas for diabetic patients by 2008 (1"The Gray Sheet" June 21, 2004, p. 26). Ryan also reported Medtronic is conducting a clinical trial to drive insulin pump therapy penetration. The study will compare insulin pumps with multiple daily injections. The exec believes that a device capable of dropping the HbA1c levels in Type 1 diabetic patients to 7% could lower diabetes healthcare costs by $100 bil. over the next 10 years...
Guardian Approval Should Give Medtronic Sizable Lead In CGMS Market
FDA approval of Medtronic's Guardian continuous glucose monitoring system gives the firm a headstart on primary competitor TheraSense's FreeStyle Navigator CGMS